Connective tissue growth factor (CTGF) is a multifunctional secreted protein, and it has been shown either to promote or suppress tumor progression among different kinds of cancers. Here, we investigated the role of CTGF in oral squamous cell carcinoma (OSCC) invasion and metastasis. In five OSCC cell lines, endogenous CTGF negatively correlated with invasiveness. Exogenous CTGF protein or forced expression of CTGF gene in the oral cancer cell line SAS significantly decreased their invasive and migratory abilities. MicroRNA (miRNA) microarray analysis was performed in CTGF-overexpressed SAS cells (SAS/CTGF-M3) versus control cells to investigate the mechanism of CTGF-mediated inhibition of OSCC invasion. Among the miRNAs regulated by CTGF, miR-504 and miR-346 were the top two miRNAs downregulated in CTGF transfectants, and the result was confirmed by quantitative reverse transcriptase-PCR. Ectopic miR-504 increased migration and invasion in SAS/CTGF-M3, however, miR-346 did not have such impact on migration/invasion. Furthermore, we identified FOXP1, a member of forkhead transcription factors, as a target gene that takes part in the miR-504-induced cellular invasion. Knockdown of FOXP1 increased invasiveness in SAS/CTGF-M3, confirming the signal axis of CTGF/miR-504/FOXP1 in OSCC. Animal experiments showed that SAS/CTGF-M3-formed orthotopic tumors were associated with a lesser invasive phenotype than control cells. Expression of miR-504 in SAS/CTGF-M3 increased lymph node metastasis, and co-expression of FOXP1 in miR-504-transfected SAS/CTGF-M3 alleviated miR-504-induced metastasis. In OSCC samples, high CTGF was associated with a lower clinical stage and a better outcome. A reverse correlation between CTGF and miR-504, miR-504 and FOXP1, and a positive correlation between CTGF and FOXP1 were shown.
Connective tissue growth factor (CTGF) is a multifunctional secreted protein, and it has been shown either to promote or suppress tumor progression among different kinds of cancers. Here, we investigated the role of CTGF in oral squamous cell carcinoma (OSCC) invasion and metastasis. In five OSCC cell lines, endogenous CTGF negatively correlated with invasiveness. Exogenous CTGF protein or forced expression of CTGF gene in the oral cancer cell line SAS significantly decreased their invasive and migratory abilities. MicroRNA (miRNA) microarray analysis was performed in CTGF-overexpressed SAS cells (SAS/CTGF-M3) versus control cells to investigate the mechanism of CTGF-mediated inhibition of OSCC invasion. Among the miRNAs regulated by CTGF, miR-504 and miR-346 were the top two miRNAs downregulated in CTGF transfectants, and the result was confirmed by quantitative reverse transcriptase-PCR. Ectopic miR-504 increased migration and invasion in SAS/CTGF-M3, however, miR-346 did not have such impact on migration/invasion. Furthermore, we identified FOXP1, a member of forkhead transcription factors, as a target gene that takes part in the miR-504-induced cellular invasion. Knockdown of FOXP1 increased invasiveness in SAS/CTGF-M3, confirming the signal axis of CTGF/miR-504/FOXP1 in OSCC. Animal experiments showed that SAS/CTGF-M3-formed orthotopic tumors were associated with a lesser invasive phenotype than control cells. Expression of miR-504 in SAS/CTGF-M3 increased lymph node metastasis, and co-expression of FOXP1 in miR-504-transfected SAS/CTGF-M3 alleviated miR-504-induced metastasis. In OSCC samples, high CTGF was associated with a lower clinical stage and a better outcome. A reverse correlation between CTGF and miR-504, miR-504 and FOXP1, and a positive correlation between CTGF and FOXP1 were shown.
Our study discovers a novel signal pathway involving the regulation of miRNA machinery by a secreted cytokine, which will be beneficial for developing therapeutic strategy against advanced OSCC.
Introduction
Oral squamous cell carcinoma (OSCC) is one of the 10 most frequent cancers worldwide with more than half a million patients being diagnosed (5% of all cancer) each year (Vokes et al., 1993; Haddad and Shin, 2008) . In Taiwan, OSCC has been the sixth leading cause of death from cancer with nearly 5400 new cases and 2200 deaths per year, and the incidence of OSCC has increased sixfold in the past decade. Despite evolution of management, the overall survival of patients has not improved significantly during the last 20 years, with 5-year survival rates between 45 and 50%. The major reason for poor prognosis is the propensity of OSCC to invade adjacent tissues. The rate of local recurrence at the primary site and regional recurrence at peripheral lymph node metastasis ranges from about 33-40% (Kademani, 2007; Wutzl et al., 2007; Jerjes et al., 2010) . However, the underlying molecular mechanisms in oral cancer are poorly understood, and there is an urgent need to identify genes that are involved in the process of invasion and metastasis.
Members of CCN family were first identified as secreted proteins whose synthesis are induced by mitogenic growth factors or oncogenes, which are deregulated in transformed cells. The first three members described-CYR61 (cysteine-rich 61; CCN1) (O'Brien et al., 1990) , CTGF (connective tissue growth factor; CCN2) and NOV (nephroblastoma overexpressed; CCN3) (Joliot et al., 1992) -provided the acronym for CCN family. CTGF is a 36-38 kDa secreted growth factor, which was initially discovered in 1991 as a secreted protein of human umbilical vascular endothelial cells (Soon et al., 2003) . It is a multifunctional signalling modulator involved in various biologic or pathologic processes, such as angiogenesis, osteogenesis, renal disease, skin disorders and tumor development (Lau and Lam, 1999; Perbal, 2001; Yosimichi et al., 2001; Planque and Perbal, 2003) . Recently, growing evidences have suggested that CTGF expression is highly associated with tumor progression, including breast cancer-induced bone metastasis (Kang et al., 2003) , glioblastoma growth (Pan et al., 2002) and poor prognosis of esophageal cancer (Koliopanos et al., 2002) . Furthermore, CTGF also acts as a migratory inducer of breast cancer cells (Chen et al., 2007) . In contrast, we have previously demonstrated that CTGF inhibits the ability of colon cancer (Lin et al., 2005) and non-small cell lung cancer (Chang et al., 2004) cells to metastasize and invade the neighboring tissue. The tumor-suppressive and metastasis-inhibitory effect of CTGF has also been demonstrated in OSCC: CTGF attenuates the growth of OSCC (Moritani et al., 2003) , and a recent report showed that CTGF inhibits OSCC motility (Chuang et al., 2011) . Therefore, these results suggest that the role of CTGF in different types of cancer may vary considerably, depending on the tissue involved. However, the impact of CTGF in regulating metastasis among different cancers and the underlying mechanisms are not fully elucidated.
MicroRNAs (miRNAs) are small noncoding regulatory RNAs ranging in size from 17 to 25 nucleotides and recent studies have revealed important roles of miRNAs and miRNA processing in tumorigenesis (Voorhoeve et al., 2006; Kumar et al., 2007; Ma et al., 2007) . Recent studies suggest the critical role of miRNAs in metastatic progression because one miRNA can regulate a set of functionally relevant genes simultaneously, which may reinforce the phenotypic change (Chan et al., 2005; Lim et al., 2005) . We hypothesized that miRNA may be involved in OSCC tumor progression and metastasis in CTGF-regulated machinery. Therefore, we sought to identify the functional roles of CTGF and the miRNAs and their downstream target genes involved in migration and invasion abilities in OSCC.
Results

CTGF expression negatively correlated with invasion and migration potential of human oral cancer cells
To study the possible role of CTGF in the invasiveness of OSCC, we first examined the correlation between invasion ability and CTGF expression in five OSCC cell lines, including TW2.6, CAL-27, HSC3, Ca9-22 and SAS. We found that CTGF mRNA and protein were highly expressed in low-invasive cells such as TW2.6, CAL-27 and HSC3 cells, but were almost undetectable in highly invasive Ca9-22 and SAS cells (Figure 1a) . The data demonstrated that CTGF expression was inversely associated with the metastatic phenotype in human oral cancer cell lines. Thus, we hypothesized that CTGF may have a critical role in oral cancer metastatic progression.
As CTGF is a secreted protein, we used the recombinant CTGF protein (rCTGF) to treat the low-CTGF-producing SAS cells and observed the impact of exogenous CTGF on cellular migration/invasion. rCTGF effectively inhibited SAS cells invasion ability in a dose-dependent manner (Figure 1b, upper) . The migration ability of SAS cells was also significantly decreased by rCTGF treatment (Figure 1b, lower) . Furthermore, we transiently transfected SAS cells with various concentrations of CTGF expression plasmid and then determined the invasion and migration abilities, and a dose-dependent decrease in invasion/ migration of SAS cells by CTGF was shown (Figure 1c) . The effect of CTGF-mediated invasion inhibition was apparently not caused by changing cell proliferation rate (Supplementary Figure 1) , which supports the major role of CTGF on OSCC migration/invasion.
To further elucidate the effect of CTGF in oral cancer cell invasion, CTGF stable transfectants in SAS cells were established. After proper selection by antibiotics, three CTGF-overexpressed clones (SAS/CTGF-C2, C7 and C28), a mixed population (SAS/CTGF-M3) and vector control (SAS/Neo) cells were established ( Figure 1d , left upper panel). A reduced invasion/ migration was shown in these CTGF stable clones (Figure 1d , left lower and right panel). In contrast, short-interference RNA-mediated knockdown of CTGF in high-CTGF-producing TW2.6 cells showed notably increased invasive ability of about 1.2B2.5-fold compared with the scrambled control (Figure 1e ). Taken together, these results indicated that CTGF significantly suppressed invasion and migration abilities in oral cancer cells.
Identification of putative downstream miRNA(s) mediating CTGF-induced migratory inhibition
To identify the mechanism(s) of CTGF-mediated inhibition in oral cancer progression, we utilized the miRNA microarray to compare the profiles of SAS/CTGF-M3 and SAS/Neo clones. Among the significantly regulated miRNAs, miR-504 and miR-346 were two of the most downregulated, and miR-1179 was upregulated in response to CTGF overexpression (Supplementary Table 1 ). Using quantitative reverse transcriptase (RT)-PCR analysis, we confirmed these changes of miRNAs expression in SAS/CTGF-M3 versus control cells. To avoid the adaptation effect in stable transfectants, rCTGF was used to treat SAS cells. A significant suppression of miR-346 and miR-504 by CTGF was shown both in stable transfection and exogenous treatment system; however, only a marginal increase in miR-1179 was found in CTGF-transfected/treated cells (Figure 2a) . The finding was confirmed in a lung adenocarcinoma cell line CL1-5 (Supplementary Figure 2 ). These results suggested that miR-346 and miR-504 may be putative CTGF downstream miRNAs participating in CTGF-induced phenotype of OSCC cells.
Repression of miR-504 by CTGF is critical in CTGF-mediated suppression of invasiveness To identify the key downstream miRNA(s) involved in CTGF-inhibited oral cancer cell migration/invasion, miR-346 or miR-504 was transfected into SAS/CTGF-M3 clone and assayed for invasion ability. As shown in Figure 2b , after confirming the miR-346 expression level in SAS/CTGF-M3, we found that there was no significant difference in invasion ability between miR-346-overexpressed SAS/CTGF-M3 and control cells. Consistently, wound-healing assay also showed no significant difference in miR-346-transfected cells (Figure 2c ). Therefore, although miR-346 was decreased in CTGF-overexpressed clone, it may not be involved in the migration/invasion inhibitory mechanism by CTGF.
To clarify the potential role of miR-504 in CTGFinhibited migration/invasion, miR-504 expressing plasmids and control vectors were transfected into low-invasive SAS/ CTGF-M3 transfectant to check the functional outcome. target databank: TargetScan, MIRADA and EIMMo, which compute optimal sequence complementarity between a set of mature miRNAs and a given mRNA using a weighted dynamic programming algorithm. From these three databanks overlapping between the predicted targets of miR-504, 44 putative downstream target genes were identified (Supplementary Table 2 ). FOXP1, PITPNA and CEP170 were ranked as the most probable targets of miR-504. We then proceeded to determine their mRNA levels in previously established CTGF stable clones. The result showed that FOXP1 was the only one with a corresponding change to CTGF manipulation in OSCC cells, that is, overexpression of CTGF in SAS cells upregulated FOXP1, and repression of CTGF in TW2.6 cells attenuated FOXP1 (Figure 4a ). To further verify the direct effect of miR-504 on FOXP1 regulation, we transiently transfected indicated concentrations of the miR-504 expression plasmid into SAS/ CTGF-M3, and FOXP1 expression was inhibited by miR-504 in a dose-dependent manner (Figure 4b) . A 3 0 -UTR reporter assay in HEK-293T cells also showed that among these three putative targets, only the FOXP1 reporter was significantly repressed by miR-504 (Figure 4c) . A similar result was obtained from the same experiment performed in SAS cells (data not shown), suggesting the FOXP1 as an important target of miR-504 in CTGF regulation machinery.
To evaluate the invasion ability and the mechanistic link between CTGF, miR-504 and FOXP1, we knock-downed FOXP1 expression by transfecting shorthairpin RNA (shFOXP1) into SAS/CTGF-M3 cells and SAS/Neo control cells and observed the migration and invasion ability in these clones. The results showed that loss of FOXP1 increased invasion (Figure 4d ) and migration (Figure 4e ) of SAS/CTGF-M3 cells, compared with SAS/Neo control cells. Collectively, these data support that suppression of miR-504 by CTGF, resulting in upregulation of FOXP1 expression contributes to CTGF-mediated inhibition of OSCC invasiveness.
Confirmation of the significance of CTGF-miR504-FOXP1 axis in vivo and in OSCC patients To confirm the effect of CTGF overexpression in OSCC progression and metastasis in vivo, CTGF stable transfectants (SAS/CTGF-M3, SAS/CTGF-C7 and SAS/ CTGF-C28) and a vector control clone (SAS/Neo) were injected into the buccal mucosa of SCID mice. All mice implanted with SAS/Neo were moribund within 40 days. As shown in Figure 5a , the overall survival was significantly longer in SAS/CTGF groups than in SAS/Neo group (Neo versus CTGF-M3, P ¼ 0.0127; Neo versus CTGF-C7, P ¼ 0.0018; Neo versus CTGF-C28, P ¼ 0.0198). Moreover, the average number of metastatic lymph nodes in mice injected with CTGFoverexpressed clone was markedly reduced by >50% compared with that of SAS/Neo control group (Figure 5b ). To further investigated the impact of CTGF-miR-504-FOXP1 axis in OSCC metastasis, we generated the stable clones by reconstitution of miR-504 (SAS/CTGF-M3/miR-504-2) or co-expression of miR-504 and FOXP1 (SAS/CTGF-M3/miR-504-2/FOXP1) in CTGF transfectants, and performed the orthotopic in vivo experiments. The results showed that reconstitution of miR-504 in SAS/CTGF-M3 correlated with a trend of shortened survival of mice (Figure 5c ; P ¼ 0.6115, log-rank test), and abrogated the metastasissuppressing effect by CTGF (Figure 5d ). Co-expression of miR-504 and FOXP1 in SAS/CTGF-M3 restored the suppression of metastasis by CTGF and extended the mice's survival (Figures 5c and d) . Finally, we investigated the clinical importance of CTGF-miR-504-FOXP1 axis in OSCC patients. Quantitative real-time RT-PCR analysis of CTGF, miR-504 and FOXP1 was performed in 85 OSCC patient tumor samples. The result showed that that high CTGF mRNA expression was significantly associated with an early TNM stage (P ¼ 0.001, Figure 6a ), and patients with a low CTGF expression were associated with a poorer prognosis (Figure 6b ). Meanwhile, a higher miR-504 expression was correlated with an advanced clinical pathological TNM stage (Po0.001, Figure 6c) . A reverse correlation between CTGF and miR-504 (Figure 6d ), miR-504 and FOXP1 (Figure 6e) , and a positive correlation between CTGF and FOXP1 ( Figure 6f) were also demonstrated.
According to our results, a novel CTGF-mediated signalling pathway model in OSCC metastasis is therefore depicted: CTGF represses miR-504 expression, which results in the augmentation of FOXP1 expression and leads to the attenuation of migratory ability and invasiveness of OSCC. Enhancement of CTGF expression or antagonist against miR-504 will reconstitute the FOXP1 expression and inhibit OSCC migration/invasion (Figure 7 ).
Discussion
The double-sided sword effect of CTGF has been widely reported in different kind of cancers: CTGF promotes cancer growth or metastasis in breast, brain and esophageal caners (Brigstock, 1999) ; in contrast, it inhibits tumor metastasis in colon and lung cancer (Hashimoto et al., 1998; Tong et al., 2001; Soon et al., 2003; Chang et al., 2004; Lin et al., 2005) . However, the role of CTGF in OSCC has been addressed limitedly, and contradictory results make the role of CTGF remain elusive: CTGF has been shown to inhibit oral tumor growth in vivo (Moritani et al., 2003) ; on the contrary, expression of CTGF was considered as a marker of bony destruction in OSCC patients (Shimo et al., 2008) . Here, we demonstrated that in human OSCC, CTGF attenuates cellular migration and invasion. Downregulation of miR-504 by CTGF contributes to CTGF-mediated inhibition of migration/invasion. We also unveiled FOXP1 as a key, albeit not the sole, component downstream of CTGF action on miR-504 activity. This is the first report to disclose the metastaticinhibitory effect by CTGF in OSCC through miRNAmediated signal pathway. miR-504 is a relatively little-known miRNA in cancer cells, and its oncogenic effect has been recently discovered: miR-504 directly represses the p53 protein expression through binding to the 3 0 -UTR of the human p53 gene, thereby negatively regulates p53-mediated apoptosis, cell cycle arrest and promotes tumorigenecity (Hu et al., 2010) . However, there is no report identifying the upstream regulator(s) of miR-504 in cancer cells. Here, we demonstrated the 'oncomir' activity of miR-504 in oral cancer: miR-504 significantly enhanced invasion and migration abilities of oral cancer cells. Furthermore, we also identified the upstream regulator of miR-504, that is, CTGF in this study, which has never been addressed before. In the orthotopic animal experiments of this study, the difference between the survival period of mice receiving implantation of SAS/ CTGF-M3 and SAS/CTGF-M3/miR-504-2 was not significant. The possible explanation is the limited case number (n ¼ 5 for each group), and unexpected prolonged survival of some mice with lymphatic metastasis.
In this study, we demonstrated FOXP1 as the key downstream target of CTGF/miR-504 through bioinformatic mining and 3 0 -UTR reporter confirmation. Furthermore, knockdown of FOXP1 in CTGF-overexpressing clones enhanced the in vitro invasion and migration abilities, suggesting the critical role of FOXP1 in CTGF/miR-504-mediated inhibition of cellular migration. In vivo study and clinical sample analysis also support the importance of FOXP1 in CTGF-mediated metastatic suppression. FOXP1 is a member of 'forkhead' (Fox) transcription factors, which have critical roles in immune responses, organ development and cancer pathogenesis (Carlsson and Mahlapuu, 2002; Katoh, 2004) . Previous studies implicated FOXP1 as a potential tumor suppressor: FOXP1 transcriptional activities appear to be inhibited in a large number of epithelial malignancies level (Banham et al., 2001) , and the location of FOXP1 on chromosome 3p14.1 is frequently associated with a loss of heterozygosity in a number of tumor types (Huebner, 2001; Zabarovsky et al., 2002) . However, the role of FOXP1 in cancer migration has never been addressed. To our knowledge, this is the first demonstration of FOXP1 involvement in the CTGFmediated invasion inhibition of human OSCC. However, the detailed mechanism regarding how FOXP1 attenuates cellular invasion remains to be determined. CTGF has been shown to bind to integrins and activate the downstream signalling (Chu et al., 2008) . A recent study reported that in monocytes, clustering of integrin a M b 2 downregulates the expression of FOXP1 through PKCd (Xue et al., 2010) . Whether CTGF regulates FOXP1 expression through the integrin-mediated signal pathway in addition to miR-504 warrants further investigation. Taken together, we suggest that miR-504 carries out its 'oncomir' function through targeting different tumor suppressors, that is, p53 and FOXP1.
CTGF is reported to bind to cellular surface proteins, such as transforming growth factor-b and integrin, and induces downstream signal pathway (Abreu et al., 2002; Chu et al., 2008) . However, there is no report linking the miRNA regulation to CTGF. Previous studies implicate the potential importance of epigenetic alteration in regulation of miRNA expression (Saito et al., 2006; Scott et al., 2006) . In this study, we have tried to investigate the role of histone modification in CTGFmediated miR-504 repression. OSCC cell lines with different CTGF levels were treated by histone deacetylase inhibitor, and the expression of miR-504 was examined. However, inconclusive results of miR-504 expression among different OSCC cell lines were noted (data not shown). Further studies are necessary to elucidate the regulatory mechanism of CTGF-mediated miR-504 repression in OSCC.
In summary, our study proposes a model that the secreted cytokine CTGF attenuates OSCC cellular invasion/migration, and we also highlight the critical role of miR-504 in promoting OSCC metastasis through regulation of a novel target, FOXP1 gene. These data serve as a foundation for future studies designed to explore further action of CTGF and miRNA expression in OSCC cancer progression. This secreted protein appears to be a potential candidate molecular protein drug to treat human oral carcinoma, and further studies are needed to clarify the additional functions.
Materials and methods
Cell lines, reagent and culture Five human OSCC cell lines were used, including CA9-22, CAL-27, HSC-3, SAS and TW2.6. The information of these five cell lines, including ethnic background, primary tumor location and culture condition are listed in Supplementary  Table 3 . Lung adenocarcinoma cell lines CL1-5 was a subline that was selected from parental CL1-0 cultures as described previously (Chu et al., 1997) . Recombinant CTGF is purchased from BioVender (Heidelberg, Germany).
miRNA microarray analysis Total RNA was isolated from SAS/CTGF-M3 cells and vector control cells with Trizol (Invitrogen Corporation, Carlsbad, CA, USA). Amplification and hybridization were performed according to the manufacturer's protocol (Illumina, Inc., San Diego, CA, USA). Illumina human V6 array was used for gene expression analysis. The raw data of the spot density was extracted from Illumina BeadStudio software and deposited into the Gene Expression Omnibus database (accession number GSE9742). Sample clustering analysis and raw data filtering (Po0.05) were performed. Quantile normalization was performed on the filtering data, followed by one-way analysis of variance to identify significant genes.
Reverse transcription and Taqman-based quantitative reverse transcription-PCR assays of miRNA expression Expressions of mature miRNAs were analyzed by TaqMan miR Assay (Applied Biosystems, Foster City, CA, USA). Briefly, complementary DNA was synthesized from total RNA (100 ng) using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). The reactions were incubated first at 16 1C for 30 min and then at 42 1C for 30 min followed by inactivation at 85 1C for 5 min. The reactions were then incubated in a 96-well plate at 50 1C for 2 min, 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min using the ABI Prism 7000 Sequence Detection System (Applied Biosystems). Relative quantification of gene expression was performed using the endogenous control gene (RNU-6B). The threshold cycle (CT) was defined as the fractional cycle number at which the fluorescence passed the fixed threshold. Relative expression was calculated using the comparative CT method.
Western blot analysis
Proteins in the total cell lysate (55 mg of protein) were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and electrotransferred onto a polyvinylidene difluoride membrane (Immobilon-P membrane; Millipore, Bedford, MA, USA). After the blot was blocked with a solution of 5% skim milk, 0.1% Tween 20 and Tris buffer saline Tween20 (TBST), membrane-bound proteins were probed with primary antibodies against CTGF and a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membrane was washed and then incubated with horseradish peroxidase-conjugated secondary antibodies for 60 min. Antibody-bound protein bands were detected with enhanced chemiluminescence reagents (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and exposed to Kodak X-Omat Blue autoradiography film (Perkin Elmer Life Sciences, Boston, MA, USA).
Plasmid construction
Single strands of miRNA were annealed to form doublestrand miRNA DNA and inserted into the BLOCK-iT Pol II miR RNAi expression vector, (pcDNA6.2-GW/EmGFP-miR; Invitrogen Corporation). SAS/CTGF-M3 cells were grown overnight and transfected with plasmid pcDNA6.2-GW/EmGFPmiR-504 to express miR-504 or empty plasmid (negative control). Blasticidin (10 mg/ml) was used to select for stable clones.
Plasmids and transient transfection
For plasmid transfection, cells were transfected with 1-3 mg plasmids using Lipofectamine 2000 reagent (Invitrogen Corporation) in Opti-MEM medium (Invitrogen Corporation) for 4-18 h, after which the medium was replaced with fresh complete medium. After 24-48 h, the transfected cells were harvested and subjected to invasion assay, wound-healing migration assay and western blot analysis. with 800-1200 mg/ml Neomycin (G418; Life Technologies Corporation, Calsbad, CA, USA). Thereafter, the selection medium was replaced every 2 days. After 2 weeks of selection in G418, resistant clones were isolated and allowed to proliferate in medium containing G418 100 mg/ml. Integration of transfected plasmid DNA was confirmed by reverse transcription-PCR and western blot analysis.
Selection of stably transfected clones
In vitro cell growth assay In all, 2 Â 10 4 cells were seeded in a 24-well plate, and further cultured for 5 days. Cell number was determined at regular intervals using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Boyden chamber assays For invasion assays, modified Boyden chambers with filter inserts (pore size, 8 mm) coated with Matrigel (20 mg; Collaborative Biomedical, Becton Dickinson Labware, Benford, MA, USA) in 24-well dishes was used. Approximately, 2 Â 10 4 cells in 100 ml of 2% fetal bovine serum Dulbecco's modified Eagle's medium were placed in the upper chamber, and 900 ml of the same medium was placed in the lower chamber. After 48 h in culture, cells were fixed in methanol for 15 min and then stained with 0.05% crystal violet in phosphate-buffered saline for 15 min. Cells on the upper side of the filter were removed with cotton swabs, and the filters were washed with phosphate-buffered saline. Cells on the underside of the filters were viewed and counted under a microscope.
Wound-healing migration assay
In all, 75 ml of 5 Â 10 5 cells per 1 ml was applied into each wound-produced culture insert (400 ± 50 mm; ibidi Gmbh, Germany) and incubated overnight. Culture inserts were removed after appropriate cell attachment. Cells were washed twice with phosphate-buffered saline and serum-free medium was added. Cell migration toward the wounded area was observed and photographed.
Real-time quantitative RT-PCR
Complementary DNA was generated using the Taqman reverse transcription kit and poly dT primer according to the manufacturer's instructions. The complementary DNA was used as template in real-time quantitative PCR reactions with CTGF and b-actin-specific primers using the ABI Prism 7000 Sequence Detection System (Applied Biosystems) at 95 1C for 
Animal metastasis experiment
In all, 6-8 weeks old female C.B.17-SCID mice (Experimental Animal Center in Medical College of National Taiwan University, Taiwan) were caged in groups. Mice were randomized to different groups receiving orthotopic injection of tumor cells into buccal mucosa (density of 10 5 cells in 20 ml phosphate-buffered saline; n ¼ 5 for each group). For lymph node metastatic models, cervical lymph nodes were excited, counted, and examined with hematoxylin and eosin pathological examination.
Luciferase reporter assay
The 3 0 UTR of human PITPNA, FOXP1 and CEP170 were amplified using PCR and cloned into a pMIR-Report vector. These constructs (1 ng) were independently co-transfected with 3 mg of control plasmid or plasmids expressing miR-504 and b-gal plasmid (0.2 ng) into 293T cells. Luciferase activity was measured 48 h after transfection using the dualluciferase reporter assay system (Promega Corporation, Madison, WI, USA).
OSCC tumor samples and clinical data collection OSCC specimens were collected at the time of surgery from previously untreated patients who underwent surgical resection at the National Taiwan University Hospital. Organization samples were snap-frozen immediately and stored at À80 1C. The histologic identification of oral cancer was determined as recommended by the World Health Organization. Tumor size, local invasion and lymph node metastasis were determined at pathologic examination. The final disease stage was determined by a combination of surgical and pathologic findings, according to the current tumor-node-metastasis staging system for oral cancer. Follow-up data were obtained from the patients' medical charts and from our tumor registry service. The survival time of patients was calculated from the date of surgery to the date of death. The relapse time was calculated from the date of surgery to the date of local recurrence or distant metastasis.
Statistical analysis
The background data of the patients with OSCC were compared using the Mann-Whitney test for scale variables (expressed as mean s.d.) and Fisher's exact test for nominal variables. Survival data were analyzed using the KaplanMeier method. Kaplan-Meier curves were compared by a log-rank test. P-values were two-sided and the significance level was 0.05.
